Sitemap
Scientific Publications
- About Us
- Overview
- DNDi Worldwide
- Business Model
- Our People
- Board of Directors
- Scientific Advisory Committee
- Ana Rabello
- Chitar Mal Gupta
- Chris Bruenger
- Dale Kempf
- Faustino Torrico
- Federico Gomez de las Heras
- François Chappuis
- Haruki Yamada
- J Carl Craft
- Khirana Bhatt
- Krisantha Weerasuriya
- Maria das Graças Henriques
- Marleen Boelaert
- Mervyn Turner
- Muriel Vray
- Nilanthi de Silva
- Nor Shahidah Khairullah
- Paul Herrling
- Pierre-Etienne Bost
- Shiva Dayal Seth
- Simon Croft
- Lisa Frigati
- Murad Shahnaz
- Team
- Friends of DNDi
- Annual Report
- DNDi's Policies
- Letter from Chairman and Executive Director
- Diseases & Projects
- Diseases
- Portfolio
- Topical Amp B (CL)
- Anfoleish (CL)
- Nitroimidazole (Chagas)
- Fexinidazole (VL)
- PI sprinkles (CHAPAS-2)
- “Superboosting” - TB/HIV
- Screening & Lead optimisation
- Nitroimidazole backup (HAT)
- Oxaborole backup (HAT)
- VL-2098
- Alt. formulations Amphotericin B
- Nitroimidazole backup (VL)
- Fenarimol series
- K777
- Flubendazole Macrofilaricide (Helminth)
- Improved PI for 1st-line
- Fexinidazole (HAT)
- Oxaborole SCYX-7158
- New VL treatments (Bangladesh)
- New VL treatments (Africa)
- New VL treatments (Latin America)
- HIV/VL
- Azoles E1224 & Biomarker (Chagas)
- ASAQ
- ASMQ
- NECT
- SSG&PM co-administration
- New VL treatments (Asia)
- Benznidazole Paedriatric dosage form
- R&D Phases
- R&D Organisation
- Building Portfolio
- Clinical Trial Protocols
- Open Innovation
- Treatments
- Strengthening Capacity
- Advocacy
- Media Centre
- Partnership
- Donors
Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License